Consun Pharmaceutical Group Ltd
HKEX:1681
Relative Value
The Relative Value of one Consun Pharmaceutical Group Ltd stock under the Base Case scenario is 6.78 HKD. Compared to the current market price of 5.98 HKD, Consun Pharmaceutical Group Ltd is Undervalued by 12%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Consun Pharmaceutical Group Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CN |
Consun Pharmaceutical Group Ltd
HKEX:1681
|
4.8B HKD | 1.7 | 5.7 | 1.6 | 1.6 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
728.1B USD | 21.3 | 138.7 | 62.7 | 72 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.9 | 46.8 | 34.2 | 37.3 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
704.3B JPY | 2.2 | 83.6 | 9.5 | 23.2 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
361.3B USD | 4.4 | 8.9 | 11.9 | 15.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
326.6B USD | 5.3 | 141.6 | 33.7 | 53.4 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
188.2B GBP | 5.1 | 39.5 | 140.7 | 225.7 | ||
CH |
Novartis AG
SIX:NOVN
|
181.4B CHF | 4.2 | 13.3 | 9.7 | 16.1 | ||
CH |
Roche Holding AG
SIX:ROG
|
171.2B CHF | 2.9 | 14.9 | 8.5 | 10.1 |